Loading patent…
OwnerCarlos de Baeremaecker Barrosinventor
Estimating the term…
A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of Trypanosoma cruzi fused to the C-terminal region. The vaccine further comprises an aluminum oxide adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion.
A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, said vaccine comprising, as active ingredient, an immunogenic component comprising a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, wherein each repetitive unit shows the following amino acid sequence:
A monocomponent vaccine comprising, as active ingredient, an effective amount of a polynucleotide codifying one or more immunogenic polypeptides derived from a Trypanosoma cruzi.
Dependencies are inferred from the claim text.